Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing blood glucose levels and safety
SEOUL, South Korea, Nov. 2, 2022 /PRNewswire/ — Daewoong Pharmaceutical (Daewoong), the South Korea-based global healthcare company, announced the phase III clinical trial results of the new diabetes drug ‘Enavogliflozin.’
Daewoong (CEO Sengho Jeon & Changjae Lee) announced on October 31th that they had revealed the results of three phase III clinical trials for Enavogliflozin monotherapy, Enavogliflozin-Metformin combination therapy, and Enavogliflozin-Metformin-Gemigliptin combination therapy at the 2022 International Congress of Diabetes and Metabolism (2022 ICDM).
All three Enavogliflozin phase 3 clinical trials confirmed the efficacy and safety for 24 weeks of dosing. The target patients for each study were as follows. For the Enavogliflozin monotherapy trial, 160 T2DM patients with inadequately controlled with diet and exercise were enrolled. For dual combination therapy trial, 200 T2DM patients with inadequate response to metformin were enrolled. For triple combination therapy trial, 270 T2DM patients with inadequate response to Metformin plus Gemigliptin were enrolled.
The Enavogliflozin monotherapy trial was a placebo-controlled superiority study. The HbA1c decreased in the Enavogliflozin group by approximately 1% over the placebo group, which was statistically significant. In addition, significant improvements were confirmed in weight, blood pressure, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) compared to the placebo group. The two combination trials, Enavogliflozin-Metformin and Enavogliflozin-Metformin-Gemigliptin combination, demonstrated non-inferiority in HbAc1 change compared to dapagliflozin 10 mg.
Soo-Heon Kwak, Professor of Endocrinology and Metabolism at Seoul National University Hospital, presented the clinical results as the lead author of the Enavogliflozin monotherapy trial at the 2022 ICDM, said, “In this monotherapy trial, we could demonstrate Enavogliflozin’s superior hypoglycemic activity and safety compared to placebo. It is expected to be an effective treatment option for T2DM patients for its hypoglycemic effect and improving metabolic abnormalities such as weight, blood pressure, cholesterol, etc.”.
Enavogliflozin is a new diabetes drug in the SGLT-2 (sodium-glucose cotransporter-2) inhibitor class, which Daewoong has been developing for the first time in South Korea. The hypoglycemic mechanism of SGLT-2 is selective inhibition of the SGLT-2 transporter involved in glucose reabsorption in the kidney’s proximal tubule to excrete glucose directly into the urine.
Phase III clinical trials of Enavogliflozin, designated as South Korea’s first drug subject to fast-track review in 2020, was approved in September 2020 for both monotherapy and metformin combination therapy, and October, metformin/Gemigliptin combination therapy. After the fast-track review, the NDA (New drug application) of Enavogliflozin was submitted in March 2022, which was 18 months from the IND submission for phase III clinical trials. Daewoong aims to get approved by MFDS this year and launch Enavogliflozin in the Korean market by the first half of 2023.
“We expect to improve the quality of life of T2DM patients around the world by promptly launching the next-generation diabetes drug, Enavogliflozin.” said Sengho Jeon, CEO of Daewoong Pharmaceutical.
SOURCE Daewoong Pharmaceutical Co., Ltd.
Related Quotes
Companies Announces Significant Initial Order for 2.33 Million Pounds of Genus Cannabis Sativa
Verve Therapeutics announced disappointing lab results for its CRISPR gene-editing approach to high cholesterol, and VERV stock skidded.
Pointing to a crowded market, a Durham drug developer has discontinued one of its clinical programs, allowing the company to shift up to $100 million toward other programs.
Shares of Moderna (NASDAQ: MRNA) climbed 2.9% on Tuesday after fellow COVID-19 vaccine maker Pfizer (NYSE: PFE) boosted its full-year sales and profit forecast. Pfizer raised the low end of its revenue guidance range to $99.5 billion from $98 billion. Most encouraging to Moderna's shareholders was Pfizer's increased sales forecast for its COVID-19 vaccine, Comirnaty.
Hospitalizations are rising again in New York City with the spread of new COVID-19 subvariants that are better at evading immunity, along with flu and respiratory syncytial virus, or RSV.
Next year, older Americans are likely to be able to receive a vaccine for the first time against respiratory syncytial virus, a common virus that can cause severe complications.
The drug company raised its revenue projection for the year despite reporting a drop in third-quarter sales from a decline in Covid-19 vaccine sales outside the U.S.
These are the healthcare stocks with the best value, fastest growth, and most momentum for November 2022.
As Covid-19 forced shutdowns in the pandemic's early days, Sunnyvale-based molecular diagnostics company Cepheid was among the first to win conditional FDA approval for a bedside viral test. Now parent company Danaher Corp. (NYSE: DHR) is shutting down a plant in Newark, eliminating 683 jobs, and cutting an additional 287 jobs at Cepheid's Sunnyvale headquarters, according to regulatory filings. In addition, a second Cepheid facility in Newark is shedding 63 jobs and a manufacturing plant in Lodi is losing 28 jobs.
When it comes to Medicare, understanding your healthcare needs and finding the right coverage are essential. But as you get close to or enter retirement, making decisions about your health can be overwhelming. To make the process a little easier, Vanguard … Continue reading → The post Vanguard's 3 Steps to Maximizing Your Medicare Coverage appeared first on SmartAsset Blog.
Is Pfizer stock a buy or a sell as it aims to gain the first approval for a maternal SRV shot? Is PFE stock a buy or a sell right now?
The deal would add heart pumps, a fast-growing part of the medical-device industry, to the J&J lineup.
Is Merck stock a buy after the company notched a third-quarter beat and raised guidance for 2022? Is MRK stock a buy now?
(Reuters) -CVS Health Corp, Walgreens Boots Alliance Inc and Walmart Inc have tentatively agreed to pay about $13.8 billion to resolve thousands of state and local government lawsuits accusing the chains of mishandling opioid painkillers, according to two people familiar with the negotiations. The proposed settlement calls for CVS to pay $5 billion over 10 years, Walgreens to pay $5.7 billion over 15 years and Walmart to pay $3.1 billion, mostly up front, according to the people. CVS, Walmart and Walgreens declined to comment.
Some people love getting up at the crack of dawn, finding that those quiet early morning hours are the best time to be productive and get grounded for the day ahead. Others get a burst of energy in the evening, reaching their peak creative state as the day winds down. But whether you're an early riser or a night owl, your sleep habits can significantly impact your health—for better or worse.A study published in the Sept. 2022 edition of Experimental Physiology found that your preferred bedtime c
Inflation is 8.3%, medical costs are up by 5.4%, the average hospital stay for Medicare patients is $13,600 and the most recent estimate is that people aged 65 will pay $315,000 for medical care during their retirement years. So what's … Continue reading → The post Here's Why Retirees Can Breathe a Sigh of Relief appeared first on SmartAsset Blog.
Pfizer says it will seek FDA approval of its respiratory syncytial virus, or RSV, vaccine, by the end of the year.
A TikTok video of a white nurse practitioner accusing a Black pregnant woman of fraud in a Philadelphia clinic has gone viral and incited outrage online.
Doctors explain the incubation period of COVID-19, what the symptoms are, vaccination benefits, and when you stop being contagious if you're infected.
Sleep experts support a switch to permanent standard time. But the Sunshine Protection Act, which the Senate passed in March, would do the opposite.
Diabeets
02/11/2022